No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: Interim results from the PURE01 study

No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: Interim results from the PURE01 study

Show other versions (1)

Bibliographic Details
Main Authors:	M. Bandini, E. Zaffuto, S. Scuderi, F. Pederzoli, L. Marandino, D. Raggi, F. Barletta, G. Gandaglia, N. Fossati, G. Burgio, M. Moschini, S. Zamboni, L. Afferi, S. Comara, A. Briganti, F. Montorsi, R. Colombo, A. Necchi, A. Gallina
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320331323

Similar Items

No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: interim results from the PURE01 study
by: G. Basile, et al.
Published: (2020-10-01)

Outcome of non-responders to neoadjuvant immunotherapy compared to cisplatin-based chemotherapy before radical cystectomy in muscle-invasive bladder cancer
by: M. Bandini, et al.
Published: (2020-07-01)

Impact of histological variants in node positive patients treated with radical cystectomy for bladder cancer
by: M. Bandini, et al.
Published: (2020-10-01)

Incongruence between TURB and radical cystectomy findings in terms of histological variant identification: Analysis of all potential clinical risk factors
by: M. Bandini, et al.
Published: (2020-07-01)

Limited vs extended lymph node dissection in T1G3 bladder cancer patients treated with radical cystectomy: is this group responsible for the negative results of the LEA trial?
by: G. Basile, et al.
Published: (2020-10-01)

Interim results of PEANUT: An open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC)
by: A. Necchi, et al.
Published: (2020-07-01)

Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy
by: S. Zamboni, et al.
Published: (2020-07-01)

Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
by: F. Scalvi, et al.
Published: (2020-10-01)

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer
by: Marco Bandini, et al.
Published: (2017-05-01)

Anatomical prostate mpMRI features and continence recovery after robot assisted radical prostatectomy: is there something beyond membranous urethral length? results from a large, multi-institutional cohort
by: M. Tutolo, et al.
Published: (2020-10-01)

A prospective, randomized, phase 3 trial assessing the impact of early Dorsal Venous Complex (eDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. Results of an interim analysis on early post-operative outcomes
by: F. Montorsi, et al.
Published: (2020-07-01)

A prospective, randomized, phase 3 trial assessing the impact of Early Dorsal Venous Complex (EDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. results of an interim analysis on early post-operative outcomes
by: F. Montorsi, et al.
Published: (2020-10-01)

Anatomical prostate mpMRI features and continence recovery after robot assisted radical prostatectomy: is there something beyond membranous urethral length? results from a large, multi-institutional cohort
by: M. Tutolo, et al.
Published: (2020-10-01)

Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course
by: Giorgio Gandaglia, et al.
Published: (2022-10-01)

Dissecting Patterns of Care in Patients With Variant Histology of Bladder Cancer and Lymph Node Invasion
by: Marco Bandini, et al.
Published: (2021-09-01)

The implementation of a prospective standardized postoperative complication system according to the EAU guidelines is associated with a decrease in the rate of adverse postoperative outcomes over time
by: G. Rosiello, et al.
Published: (2020-07-01)

How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
by: A. Stabile, et al.
Published: (2020-07-01)

When to omit lymphadenectomy during radical prostatectomy in patients with clinical localized prostate cancer: A clinical net benefit analysis weighting staging accuracy, risk of morbidity and life expectancy
by: A. Larcher, et al.
Published: (2020-07-01)

Is focal ablation as effective as hemi-ablation? analysis of treatment patterns over 12 years from a high volume centre for focal therapy
by: A. Stabile, et al.
Published: (2020-10-01)

How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
by: F. Barletta, et al.
Published: (2020-10-01)

Association between BRCA 1/2 polymorphisms and disease aggressiveness in a prospective cohort of prostate cancer patients undergoing radical prostatectomy
by: V. Cucchiara, et al.
Published: (2020-07-01)

The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer
by: A. Stabile, et al.
Published: (2020-07-01)

The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer
by: G.O. Cirulli, et al.
Published: (2020-10-01)

Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
by: Daniele Raggi, et al.
Published: (2021-08-01)

Focal therapy for prostate cancer: do apical lesions correlate with worse outcomes?
by: A. Stabile, et al.
Published: (2020-10-01)

Is focal ablation as effective as hemi-ablation? Analysis of treatment patterns over 12 years from a high volume centre for focal therapy
by: A. Stabile, et al.
Published: (2020-07-01)

Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer
by: A. Necchi, et al.
Published: (2020-07-01)

A positive PSMA PET/CT Predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
by: L. Nocera, et al.
Published: (2020-10-01)

Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: Results from the national cancer database
by: A. Martini, et al.
Published: (2020-07-01)

Enhanced recovery after surgery (ERAS) in radical cystectomy patients: from consensus to evidences
by: Marco Moschini, et al.

A positive PSMA PET/CT predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
by: D. Robesti, et al.
Published: (2020-07-01)

Should we target all visible areas at mp-MRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
by: A. Stabile, et al.
Published: (2020-07-01)

Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis
by: Wojciech Krajewski, et al.
Published: (2021-02-01)

Development of a risk calculator of recurrence in inguinal lymph-node metastatic (ILNM) patients with surgically-resected penile squamous-cell carcinoma (PSCC)
by: M. Bandini, et al.
Published: (2020-07-01)

Regression-tree analysis for identifying the best candidates to neoadjuvant chemotherapy in patients with clinical node-positive penile squamous-cell carcinoma
by: M. Bandini, et al.
Published: (2020-07-01)

Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer
by: Simone Scuderi, et al.
Published: (2023-06-01)

Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series
by: A. Stabile, et al.
Published: (2020-07-01)

Prostate Cancer: Is There Still a Role for Systematic Biopsies? Yes
by: Giorgio Gandaglia, et al.
Published: (2022-04-01)

Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series
by: E. Mazzone, et al.
Published: (2020-10-01)

Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data
by: A. Martini, et al.
Published: (2020-10-01)